



Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly

Pal Pacher¹, Sabine Steffens², György Haskó³, Thomas H. Schindler⁴ and George Kunos⁵

Abstract | Dysregulation of the endogenous lipid mediators endocannabinoids and their G-protein-coupled cannabinoid receptors 1 and 2 (CB₁R and CB₂R) has been implicated in a variety of cardiovascular pathologies. Activation of CB₁R facilitates the development of cardiometabolic disease, whereas activation of CB₂R (expressed primarily in immune cells) exerts anti-inflammatory effects. The psychoactive constituent of marijuana, Δ^9 -tetrahydrocannabinol (THC), is an agonist of both CB₁R and CB₂R, and exerts its psychoactive and adverse cardiovascular effects through the activation of CB₁R in the central nervous and cardiovascular systems. The past decade has seen a nearly tenfold increase in the THC content of marijuana as well as the increased availability of highly potent synthetic cannabinoids for recreational use. These changes have been accompanied by the emergence of serious adverse cardiovascular events, including myocardial infarction, cardiomyopathy, arrhythmias, stroke, and cardiac arrest. In this Review, we summarize the role of the endocannabinoid system in cardiovascular disease, and critically discuss the cardiovascular consequences of marijuana and synthetic cannabinoid use. With the legalization of marijuana for medicinal purposes and/or recreational use in many countries, physicians should be alert to the possibility that the use of marijuana or its potent synthetic analogues might be the underlying cause of severe cardiovascular events and pathologies.

The 2016 report from the WHO on *The Health and Social Effects of Nonmedical Cannabis Use* states that marijuana or cannabis use is a risky behaviour with potentially harmful health consequences, including adverse cardiovascular effects¹. The report also notes the dramatic increase in the potency of cannabis over the past decade, attributable to the increase in its Δ^9 -tetrahydrocannabinol (THC) content from around 2–3% up to 20%, as a likely factor in the rise in cannabinoid receptor 1 (CB₁R)-mediated adverse cardiovascular effects. Since 1998, the use of cannabis for medical purposes has become legal in 29 states (according to state, but not federal law) in the USA, and numerous countries have also opted to legalize marijuana for medicinal use. The 2017 Cannabis Industry Annual Report (from New Frontier Data) estimated the legal cannabis market to be worth US\$7.97 billion in the USA in 2017, with projected total market sales to exceed \$24 billion by 2025, and possibly driving the creation of 300,000 new jobs by 2020, more than any other sector in the economy².

Another potentially dangerous development has been the increasing availability and recreational use of a growing number of psychoactive synthetic cannabinoids with

potencies 10-times to 200-times greater than that of THC. These 'designer' drugs are commonly mixtures of several potent synthetic CB₁R agonists such as AB-CHMINACA, AB-FUBINACA, AB-PINACA, AKB4, AM-2201, cannabicyclohexanol, CP 55,940, HU210, JWH-018, JWH-073, JWH-200, UR-144, and XLR-11, to name just a few among several hundred largely unknown variants estimated by the United Nations Office on Drugs and Crime to be in circulation worldwide³, with only 26 being considered as schedule I drugs by the Drug Enforcement Administration. These compounds and their mixtures, often sprayed on harmless herbs, or mixed with oily solutions or brownies, circulate most commonly as Black Mamba, Bombay Blue, fake weed, K2, and spice, but several hundred other names have been used. Strikingly, a new generation of these designer drugs are reported to be up to 170-times more potent than THC in activating CB₁R, with a dramatic increase in potency noted within the past 2 years⁴. These drugs were also responsible for recent clusters of poisoning outbreaks involving up to hundreds of individuals in Alabama, New York⁵, and Mississippi⁶, with numerous deaths reported. According to the Centers for Disease

Correspondence to P.P.
Laboratory of Cardiovascular
Physiology and Tissue Injury,
National Institutes of
Health/NIAAA, 5625 Fishers
Lane, Bethesda, Maryland
20892, USA.
pacher@mail.nih.gov

doi:10.1038/nrcardio.2017.130
Published online 14 Sep 2017

Key points

- Activation of cannabinoid receptor 1 (CB₁R) by endocannabinoids or synthetic ligands mediates acute haemodynamic effects and might contribute to pathology in cardiovascular disease; activation of cannabinoid receptor 2 (CB₂R) exerts anti-inflammatory effects
- The psychoactive constituent of marijuana, Δ^9 -tetrahydrocannabinol (THC), exerts its cardiovascular effects via CB₁R activation; at low doses it might have beneficial properties via partial activation of CB₁R and CB₂R, and unrelated mechanisms
- The composition of marijuana (THC–cannabidiol ratio, terpenoids) can influence its therapeutic and cardiovascular adverse effects, with marijuana smoke being as harmful as tobacco smoke
- Most synthetic cannabinoids used for recreational use are full agonists of CB₁R (THC is a partial agonist) with up to several hundred-fold higher potency and efficacy than THC, causing more dangerous adverse effects
- In parallel with a tenfold increase in the THC content of marijuana and the widespread availability of synthetic cannabinoids for recreational use, the number of serious cardiovascular adverse effects reported has markedly increased
- Clinicians should be vigilant to recognizing potential cardiovascular effects of marijuana and synthetic cannabinoids; controlled clinical trials should determine the long-term consequences of the use of medical marijuana on cardiovascular morbidity and mortality

Control and Prevention (CDC), there were 3,572 calls to poison centres in the USA in the first half of 2015 owing to synthetic cannabinoids, a 229% increase from the same period in 2014 (REF. 7). The appearance of new and more potent spice variants also coincided with the increase in fatalities. The Mississippi outbreak alone was associated with nine synthetic cannabinoid-related deaths⁶.

Numerous case reports and clinical studies during the past decade have linked acute or chronic marijuana and/or synthetic cannabinoid use with serious adverse cardiovascular events, including stroke, myocardial infarction, cardiomyopathy, arrhythmias, and cardiac arrest, which will be discussed in this Review, along with the role of the endocannabinoid system in cardiovascular disease, and its potential as a therapeutic target.

ECS in cardiovascular health

To facilitate the understanding of the acute and chronic consequences of marijuana and synthetic cannabinoid use, this section presents an overview on the role of the endocannabinoid system (ECS) in cardiovascular health and disease (reviewed in detail previously^{8–12}). The ECS comprises endogenous lipid mediators or endocannabinoids (arachidonoyl ethanolamide [AEA or anandamide] and 2-arachidonoylglycerol [2-AG]), their biosynthetic

and metabolic enzymes, and G-protein-coupled CB₁R and cannabinoid receptor 2 (CB₂R) (REFS 13–15), which also mediate the effects of the psychoactive component of marijuana, THC. At higher concentrations, endocannabinoids can also interact with additional receptors, such as the transient receptor potential cation channel subfamily V member 1 (TRPV1)¹⁶.

CB₁R are the most abundant G-protein-coupled receptors in the mammalian brain, and are responsible for mediating the psychoactive effects of marijuana. Low, but functional, levels of CB₁R have also been detected in most peripheral tissues, including the heart and vasculature^{17–19}. CB₂R are normally expressed in immune and immune-derived cells, but can be induced in other tissues under certain pathological conditions²⁰. Cannabinoid receptors signal via G_{i/o}-protein-dependent pathways to inhibit adenylyl cyclase and modulate ion-channel function, but also activate mitogen-activated protein kinases (p44/42 MAPKs, p38, ERK, and JNK) or ceramide signalling^{16,21}, and can also engage G-protein-independent pathways via β -arrestins^{22,23}.

The biosynthesis of endocannabinoids occurs ‘on demand’ and can involve multiple pathways. Hydrolytic conversion of the precursor *N*-acyl-phosphatidylethanolamine (NAPE) via NAPE-selective phospholipase D (NAPE-PLD) leads to formation of anandamide, the first endocannabinoid discovered²⁴. Additional parallel biosynthetic pathways of anandamide have also been identified^{25,26}. The synthesis of 2-arachidonoylglycerol (2-AG), the second endocannabinoid identified, is largely driven by the sn1-specific diacylglycerol lipase: DGL α in the brain and DGL β in the periphery^{27–29}. Endocannabinoids have a short *in vivo* half-life³⁰ owing to their rapid degradation into arachidonic acid and other metabolites through the activity of fatty-acid amide hydrolase (FAAH)³¹, monoglyceride lipase (MGL)³², and other enzymes, including cyclooxygenase 2 (also known as prostaglandin G/H synthase 2) and lipoxygenases^{33,34}. The ECS has been comprehensively reviewed previously^{35–37}.

In the cardiovascular system, cannabinoid receptors are located in the myocardium^{38–43}, vascular endothelial and smooth muscle cells^{44–47}, as well as circulating blood cells⁴⁸. CB₁R are also present in the peripheral nervous system^{49,50}, including vagal afferent neurons⁵¹, and can modulate cardiovascular function. Endocannabinoid synthesis has been detected in rat isolated kidney microvascular endothelial cells⁴⁵, human umbilical vein endothelial cells, aortic smooth muscle cells^{44,52}, human platelets⁵³, monocytes^{54,55}, THP-1-derived macrophage foam cells⁵⁶, lymphocytes⁵⁷, and dendritic cells⁵⁸. These cells are also involved in endocannabinoid hydrolysis^{45,52,57,59}. Other cells, including human neutrophils, can also hydrolyse endocannabinoids into metabolites including arachidonic acid, which is further metabolized into pro-inflammatory eicosanoids in these cells⁶⁰. Endocannabinoids act locally in a paracrine or autocrine manner by activating cannabinoid receptors, as shown for example in isolated blood vessels⁶¹. In human or mouse primary vascular smooth muscle cells, pharmacological antagonism or genetic deficiency of cannabinoid receptors modulates tumour necrosis factor (TNF)- α or

Author addresses

¹Laboratory of Cardiovascular Physiology and Tissue Injury, National Institutes of Health/NIAAA, 5625 Fishers Lane, Bethesda, Maryland 20892, USA.

²Institute for Cardiovascular Prevention, Ludwig-Maximilians-University and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Pettenkoferstrasse 8a und 9b, Munich, D-80336, Germany.

³Department of Surgery, Rutgers New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, USA.

⁴Department of Radiology, Johns Hopkins University, 601 North Caroline Street, Baltimore, Maryland 21287, USA.

⁵Laboratory of Physiological Studies, National Institutes of Health/NIAAA, 5625 Fishers Lane, Bethesda, Maryland 20892, USA.

platelet-derived growth factor (PDGF)-mediated cellular responses, suggesting that inflammatory stimuli induce endocannabinoid-mediated cannabinoid-receptor signalling in an autocrine manner^{46,62–64}.

Endocannabinoids exert complex cardiac and vascular effects ranging from vasodilatation to vasoconstriction, and decreased myocardial contractility, depending on the vessel type and experimental condition (reviewed in detail previously^{11,17,65–67}). In human cultured primary cardiomyocytes⁴² and human coronary artery and umbilical endothelial cells^{47,68}, CB₁R activation triggers p38 and JNK MAPK signalling, which promotes cell death. In the intact organism, endocannabinoids have complex haemodynamic effects mediated by CB₁R in the vasculature, myocardium, and neurons in the central and autonomic nervous systems, leading to decreased myocardial contractility and blood pressure^{65,69–71}. These effects are similar to the effects of synthetic CB₁R agonists⁷², only of much

shorter duration owing to the rapid degradation of endocannabinoids in peripheral tissues, including the heart and vasculature. In contrast to CB₁R agonists, which exert potent cardiovascular depressive effects in experimental animals⁶⁵, CB₂R agonists are devoid of cardiovascular effects^{10,12}. The normal cardiovascular function in *Cnr1* (encoding CB₁R), *Cnr2* (encoding CB₂R), *Faah*, *Mgl1*, or *Trpv1* knockout mice indicates that endocannabinoids under normal conditions are not tonically active¹⁷.

ECS in cardiovascular disease

Preclinical studies

Cardiovascular collapse, cardiomyopathy, and heart failure. Interest in studying the role of the ECS in cardiovascular disease (FIG. 1) was rekindled by the discovery that endocannabinoids are overproduced by activated immune or endothelial cells and cardiomyocytes under pathological conditions, such as those associated




Figure 1 | Pathophysiological effects of the endocannabinoid system in health and disease. Endocannabinoids are overproduced during tissue injury and through cannabinoid receptor 1 (CB₁R) contribute to hypotension and decreased cardiac function associated with various pathologies (such as various forms of shock, cardiomyopathies, and heart failure). Endocannabinoid–CB₁R signalling via p38 and JNK mitogen-activated protein kinase (MAPK) activation and increased reactive oxygen species (ROS) generation also contributes to endothelial and cardiomyocyte cell death and cardiovascular dysfunction. In macrophages, CB₁R signalling promotes inflammatory and ROS signalling and also contributes to the development of vascular inflammation and atherosclerosis. In fibroblasts, CB₁R signalling is profibrotic. CB₁R signalling in central and peripheral nervous systems can also induce stimulation or inhibition of sympathetic and parasympathetic activity (largely dependent on dose, route of administration, and duration of the use of marijuana or synthetic cannabinoids, and on individual sensitivity). By contrast, CB₂R stimulation in immune and activated endothelial cells decreases the acute inflammatory response (chemotaxis, adhesion, and transmigration of inflammatory cells) and consequent oxidative stress, for example associated with acute myocardial infarction, and might exert beneficial effects on cardiomyocytes. Chronic treatment with CB₂R agonists also has antiatherosclerotic and antifibrotic effects in animal models. In contrast to CB₁R stimulation, CB₂R stimulation has no direct cardiovascular effects. Endocannabinoids are rapidly metabolized by fatty-acid amide hydrolase (FAAH), monoglyceride lipase (MGL), cyclooxygenases (COXs), and other enzymes to arachidonic acid (AA), and under particular conditions to various oxidized endocannabinoids. Consequently, under pathological conditions, endocannabinoids might be a substantial source of pro-inflammatory, anti-inflammatory, and vasoactive eicosanoids. The role of endocannabinoids in cardiovascular pathology is complex and might depend on the disease and stage of progression.

with various forms of circulatory (haemorrhagic⁷³, septic⁷⁴, or cardiogenic^{55,75}) shock, cardiomyopathies (doxorubicin-induced⁴³, diabetic⁴¹, or associated with advanced liver cirrhosis^{54,76}), and chronic ischaemia-induced heart failure⁷⁷, and contribute to acute cardiovascular collapse (hypotension or cardiodepression) via CB₁R signalling (BOX 1). These studies demonstrated that CB₁R antagonists (such as rimonabant) not only markedly improved the pathological haemodynamic alterations when administered acutely⁸, but also attenuated cell death, inflammation, and adverse tissue remodelling, and improved metabolic parameters in chronic treatment regimens^{41,43,77–80}. Genetic deletion of the AEA-metabolizing enzyme FAAH was associated with increased CB₁R-dependent cardiac dysfunction, inflammation, cell death, and mortality in a doxorubicin-induced cardiomyopathy model⁷⁸.

In contrast to the deleterious effects of CB₁R activation, selective CB₂R agonists are cardioprotective in models of myocardial infarction^{40,81–83}, stroke^{84,85}, and restenosis⁶³, which is largely owing to the attenuation of

inflammatory responses and of the interaction between activated endothelium and inflammatory cells (chemotaxis, rolling, adhesion, and transmigration) — a subject reviewed extensively previously^{10,20,67,86,87}.

Atherosclerosis and stroke. A number of reports have demonstrated that cannabinoids and their endogenous counterparts can modulate plaque development in experimental models of atherosclerosis. THC at low doses was found to have antiatherosclerotic effects by reducing pro-inflammatory cytokine production and macrophage migration, thereby leading to reduced plaque development⁸⁸. Similar effects were observed with the synthetic cannabinoid WIN55212-2 (REFS 89,90). In these studies, the antiatherogenic effect was inhibited by CB₂R antagonism, suggesting an atheroprotective role for CB₂R signalling^{88–90}. Accordingly, the deletion of *Cnr2* in mice with an atherosclerosis-prone background (*Apoe*^{−/−}) or LDL-receptor deficiency (*Ldlr*^{−/−}) resulted in higher plaque content of macrophages^{91–93}, lipids⁹³, smooth muscle cells, and collagen⁹¹. *In vitro*, reduced susceptibility of macrophages from *Cnr2*^{−/−} mice to undergo oxidized LDL-induced apoptosis was reported⁹⁴. This finding is in accordance with a reduced number of apoptotic cells in plaques of *Cnr2*^{−/−}*Ldlr*^{−/−} mice⁹¹. However, plaque size was not different in CB₂R-deficient *Apoe*^{−/−} or *Ldlr*^{−/−} mice compared with controls^{91–93}, whereas chronic treatment with the CB₂R agonist JWH133 reduced atherosclerotic plaque development in *Apoe*^{−/−} mice⁹². Other investigators found no anti-inflammatory effects of JWH133 in *Ldlr*^{−/−} mice⁹³. Overall, these findings support the notion that pharmacological or endogenous stimulation of CB₂R inhibits atherosclerotic plaque development and inflammation.

This notion is in contrast to the suggested proatherogenic role of CB₁R⁹⁵. CB₁R blockade substantially reduced plaque development in *Ldlr*^{−/−} mice, accompanied by reductions in food intake, weight gain, and cholesterol levels⁹⁶. Further experiments suggest that CB₁R blockade has antiatherogenic effects independent of reduced weight gain and, at least at lower doses, independent of changes in plasma cholesterol levels⁹⁶. Reduced pro-inflammatory cytokine expression in macrophages might explain, at least in part, the inhibitory effect of CB₁R antagonism on plaque development in experimental atherosclerosis^{96,97}. Furthermore, endogenous CB₁R activation decreases cholesterol transporter ATP-binding cassette subfamily A member 1 (ABCA1) expression in macrophages, which is not only crucial for cellular cholesterol clearance⁹⁸, but is also involved in suppressing haematopoietic stem cell proliferation⁹⁹. Decreased expression of ABCA1 enhances leukocytosis in hypercholesterolaemic mice, which triggers atherogenesis¹⁰⁰. In another study, chronic rimonabant treatment did not affect plaque size and composition in *Apoe*^{−/−} mice, but improved endothelium-dependent vasodilatation in isolated aortas, together with decreased expression of type 1 angiotensin II receptor, activity of NADPH oxidase, and production of reactive oxygen species¹⁰¹. In accordance with a pro-inflammatory role of CB₁R in atherosclerosis, CB₁R expression is higher in coronary artery plaques from patients with unstable versus stable angina⁹⁷.

Box 1 | Pathological consequences of cannabinoid receptor 1 signalling

Cardiomyocytes

- p38 and JNK mitogen-activated protein kinases (MAPKs) activation, apoptosis
- ERK1/2 activation and cardiac hypertrophy?
- Increased generation of reactive oxygen species
- Decreased contractility
- Decreased mitochondrial biogenesis?

Endothelium

- p38 and JNK MAPKs activation, apoptosis
- Pro-inflammatory response (nuclear factor-κB activation and increased expression of adhesion molecules)
- Chronic endothelial dysfunction
- Acute endothelial-dependent relaxation in particular vessels (uncertain whether this effect is irreversible, causing initial release and subsequent depletion of nitric oxide)

Vascular smooth muscle

- Vascular smooth muscle proliferation and migration, and neointima proliferation (Rac, ERK1/2-dependent?)
- Type 1 angiotensin II receptor–NADPH oxidase-dependent generation of reactive oxygen species and vascular dysfunction

Fibroblasts and myofibroblasts

- Profibrotic effect (enhanced transforming growth factor-β signalling? Secondary consequence of oxidative stress and pro-inflammatory response?)

Macrophages

- Generation of reactive oxygen species, p38 MAPK-dependent pro-inflammatory response (tumour necrosis factor-α, IL-1β, and C-C motif chemokine 2 secretion)
- NLRP3 inflammasome activation
- Accumulation of oxidized LDL
- Macrophage chemotaxis

Adipocytes

- Decreased adiponectin secretion
- Enhanced lipogenesis and decreased lipolysis
- Decreased mitochondrial biogenesis
- Promotion of differentiation (increased cell size)
- Decreased insulin sensitivity

Other studies focused on endocannabinoid metabolic pathways to clarify the contribution of endocannabinoids to atherosclerosis. *Faah*^{-/-} mice have elevated levels of anandamide and related *N*-acylethanolamines sharing the same metabolic pathway. Genetic FAAH deficiency on the *Apoe*^{-/-} background inhibited plaque growth, but despite smaller size, these plaques had a higher neutrophil content and increased expression of the plaque-destabilizing enzyme matrix metalloproteinase (MMP) 9, but fewer smooth muscle cells¹⁰². This change might be related to enhanced recruitment of neutrophils into the plaque, as shown by live imaging of carotid arteries under hypercholesterolaemic conditions¹⁰². In support of these findings, treatment of *Apoe*^{-/-} mice with an FAAH inhibitor resulted in increased plaque neutrophil content and MMP9 expression, but reduced collagen content¹⁰³. These findings suggest that targeting FAAH might modulate plaque composition towards a more unstable phenotype. Montecucco and colleagues reported elevated 2-AG levels in advanced atherosclerotic plaques of the aortas of *Apoe*^{-/-} mice fed a high cholesterol diet, suggesting a potential role of 2-AG in promoting atherosclerosis¹⁰⁴. In another study, myeloid-specific deletion of sn1-specific diacylglycerol lipase, a key biosynthetic enzyme of 2-AG, inhibited atherogenesis in *Apoe*^{-/-} mice, suggesting that 2-AG generated in myeloid cells might promote vascular inflammation and atherogenesis¹⁰⁵.

Several earlier studies found beneficial effects of non-selective CB₁R agonists in rodent models of stroke, but these protective effects were subsequently attributed to CB₁R-mediated hypothermia, which does not occur in humans, and protective effects of CB₁R antagonists were also described in the same models^{12,67}. Several studies investigating the role of CB₂R in stroke found that CB₂R agonists decreased endothelial cell activation, attachment of inflammatory cells to the activated endothelium, rolling, transmigration, and consequent tissue inflammation and injury^{10,67}.

Clinical studies

CB₁R antagonists in obesity. The ECS has an important role in the peripheral and central regulation of energy homeostasis as well as lipid and glucose metabolism, and patients with metabolic abnormalities have an overactivity of this system^{106–108}. Patients with metabolic disorders such as obesity, dyslipidaemia, and diabetes mellitus have an increased risk of developing cardiovascular disease¹⁰⁹. In this context, clinical studies that have been conducted with the CB₁R antagonist/inverse agonist rimonabant are of particular interest not only because of its beneficial effects on visceral obesity, but also because of improvements in related cardiometabolic risk factors⁹⁵. In large-scale, multicentre, phase III trials conducted in the early 2000s, rimonabant was beneficial in causing weight loss; improving HDL-cholesterol, triglyceride, fasting glucose, and insulin levels; decreasing insulin resistance, and reducing the prevalence of metabolic syndrome^{110–116}. On the basis of these promising findings, the ADAGIO-Lipids trial¹¹¹ was designed to study the effect of rimonabant on HDL-cholesterol and triglyceride levels as primary end points in obese patients with atherogenic dyslipidaemia.

Secondary end points included changes in visceral and liver fat, which were measured using CT. Rimonabant significantly improved the primary end points and other circulating lipid markers, as well as C-reactive protein and adiponectin levels. In addition, a significant loss of visceral fat and mobilization of liver fat in individuals treated with rimonabant was reported, suggesting a beneficial effect on atherosclerosis in patients with dyslipidaemia and excess visceral adiposity and liver fat.

Subsequent clinical studies with rimonabant in patients with obesity specifically focused on primary cardiovascular end points^{117–119}. The aim of the STRADIVARIUS trial¹¹⁷ was to investigate whether rimonabant reduces coronary atherosclerosis in patients with abdominal obesity. The primary end point was the change in percent atheroma volume after 18 months of 20 mg rimonabant daily, monitored using intravascular ultrasonography. Disappointingly, the study showed no improvement in the primary end point, although the secondary end point (normalized total atheroma volume) was significantly decreased¹¹⁷. Concerns were raised about high rates of adverse neuropsychiatric events in the rimonabant treatment group¹²⁰. Similarly, the AUDITOR trial¹¹⁹ found no significant effect of rimonabant on the primary end point of quantitative progression of atherosclerosis, as assessed by noninvasive ultrasonography measurement of carotid artery intima-media thickness. Despite significant reduction in body weight and waist circumference, and increased HDL-cholesterol levels in patients receiving rimonabant in both the STRADIVARIUS and AUDITOR trials, these changes were apparently insufficient to affect progression of atherosclerosis. The CRESCENDO trial¹¹⁸ was designed to investigate whether rimonabant reduces the risk of myocardial infarction, stroke, or death as a result of acute cardiovascular events in patients with obesity at increased cardiovascular risk. Owing to safety concerns related to increased incidence of psychiatric disorders (depression, anxiety, and suicide) in patients receiving rimonabant, the drug was suspended in November 2008 and finally withdrawn from the market in Europe in January 2009; rimonabant was never approved in the USA for similar reasons¹²¹. Despite the premature discontinuation of the CRESCENDO trial¹¹⁸, data from >9,000 individuals in both the rimonabant and placebo groups were collected with a mean follow-up of 13.8 months, and revealed no difference in the primary end points of myocardial infarction, stroke, and survival. Although the numbers of successful suicide attempts in the placebo and treatment groups (one versus four) were probably clinically irrelevant, the study was prematurely terminated.

Endocannabinoid–CB₁R signalling and cardiovascular risk. Plasma levels of AEA and 2-AG in individuals with obesity were positively correlated with coronary circulatory dysfunction¹²² and coronary endothelial dysfunction¹²³, raising the possibility of using plasma endocannabinoid levels as biomarkers of cardiovascular risk in obesity. Humans and mice with severe obesity also had increased myocardial CB₁R levels determined by PET imaging and/or absolute quantification using

digital droplet polymerase chain reaction¹²⁴. CB₁R was upregulated in epicardial fat from human ischaemic hearts¹²⁵ and in atherosclerotic plaques of patients with unstable angina⁹⁷.

Genetic studies. Association studies of genetic polymorphisms with complex diseases help to clarify whether pathogenic factors identified in animal disease models might be relevant for human pathophysiology, but do not prove a causal relationship. Several polymorphisms in genes encoding proteins involved in the ECS have been associated with abnormal lipid homeostasis and other cardiometabolic risk factors^{126–130}, suggesting that genetic variations affecting endocannabinoid signalling might predispose to cardiovascular disease.

In particular, genetic variations in the gene encoding the CB₁R, *CNR1*, and its promoter have been linked to abnormal HDL-cholesterol levels^{126,128–130}. The association between dyslipidaemia and *CNR1* gene variations was in part independent of BMI, as shown in a family cohort study (the TOPS study¹²⁶) using six representative nucleotide polymorphisms (tagSNPs) and haplotype-based association analysis. The identified haplotype H4 associated with higher BMI, insulin resistance, and dyslipidaemia contains a unique SNP within the *CNR1* promoter which is directly associated with HDL-cholesterol levels. A second promoter SNP identified in the same family cohort study is associated with triglyceride and total cholesterol levels, but not HDL-cholesterol levels. A subsequent study further characterized the relationship between 22 tagSNPs in the *CNR1* gene and dyslipidaemia in individuals with very severe obesity (BMI >40 kg/m²)¹²⁸. In this study, a genetic variation (the H3 haplotype) was described that protects against obesity-related dyslipidaemia, namely a decrease in HDL-cholesterol level, which usually accompanies weight gain. However, the causal variants in this region responsible for the association were unidentified. Of note, there are sex-specific differences in the relationship between *CNR1* variations and HDL-cholesterol response to changes in dietary fat intake¹³⁰. In 2013, rs806371 was identified as a causal variant in the *CNR1* promoter that links CB₁R expression to HDL-cholesterol level¹²⁹. Functional *in vitro* experiments confirmed that rs806371 enhances DNA-protein binding and reduces *CNR1* promoter activity.

Moreover, SNPs in the *FAAH* gene have been associated with obesity¹³¹ and obesity-related dyslipidaemia¹²⁷. Again using the TOPS obesity family study cohort and five haplotype tagSNPs for the *FAAH* gene, only rs324420, a previously identified coding SNP (C385A) linked with obesity¹³¹, was associated with BMI, and triglyceride and HDL-cholesterol levels, but not insulin sensitivity¹²⁷. The same SNP was associated with worse cardiometabolic profile (weight, adipocytokines levels, TNF- α level, and insulin resistance) in patients with diabetes mellitus¹³².

Little is known about associations between *CNR2* gene variants and cardiovascular risk. Only one large-scale study, the German MI family study¹³³, is available in the literature, in which associations between common *CNR2* polymorphisms and myocardial infarction or

cardiovascular risk were analysed. In this study, 13 SNPs essentially within the *CNR2* coding region (that is, the second exon) as well as 5' and 3' untranslated regions were analysed, and no significant association between the 13 SNPs and myocardial infarction or traditional cardiovascular risk factors (obesity, hypertension, hypercholesterolaemia, and diabetes mellitus) was found.

Taken together, human genetic studies suggest that the endocannabinoid–CB₁R axis is involved in maintaining lipid homeostasis, and that unbalanced signalling under pathophysiological conditions might trigger dyslipidaemia, thereby promoting atherosclerosis.

Cardiovascular effects of marijuana

The *Cannabis sativa* plant contains >700 different chemical compounds, including 104 unique cannabinoids^{134,135}. The principal psychoactive cannabinoid in the plant is THC (a partial agonist of both CB₁R and CB₂R), which underlies most of the CB₁R-mediated adverse effects on the cardiovascular and central nervous systems, whereas cannabidiol is a nonpsychoactive compound, which has also been shown to exert antioxidant and anti-inflammatory properties in various models of tissue injury^{134,136}. Similarly to cannabidiol, some other minor constituents of marijuana (discussed below) might also exert beneficial actions.

The cardiovascular effects of marijuana largely depend on several factors, including composition of the plant (the higher the THC content in the plant, the higher the likelihood of CB₁R-mediated cardiovascular effects) and the route of administration (inhalation route can lead to rapid increases in plasma levels with more rapid decline, whereas oromucosal administration of marijuana extracts, such as nabiximols, or pure THC can result in lower, but more stable levels; fat in the food can enhance oral absorption if ingested orally, such as in brownies). Depending on smoking methods and inhalator used, the inhaled amount of toxic burn products as well as THC can vary considerably. Another factor is the quality of the soil — the marijuana plant can accumulate large amounts of heavy metals, pesticides, fungi, and various toxins from the soil.

Beneficial effects

Cannabidiol is the most or second most abundant cannabinoid in the marijuana plant, depending on the variety. Cannabidiol does not stimulate CB₁R and has no psychoactive properties. Initially, it was considered to be devoid of biological activity, until a study by Nobel Laureate Julius Axelrod and his group discovered that both cannabidiol and THC were neuroprotective antioxidants with a potency exceeding that of many known reference antioxidants¹³⁷. Subsequently, a large number of preclinical studies demonstrated potent anti-inflammatory effects of cannabidiol in neuroinflammation, neurodegeneration, colitis, liver and kidney injury, primary diabetes^{138–140}, and diabetic complications^{134,141,142}. On the basis of *in vitro* assays, numerous mechanisms have been proposed to account for the anti-inflammatory and tissue-protective effects of cannabidiol, but these mechanisms have not been validated *in vivo*¹³⁴.

Beneficial effects of cannabidiol were demonstrated in animal models of myocardial infarction^{143,144}, stroke^{145–151}, doxorubicin-induced and diabetic cardiomyopathies^{152–154}, and autoimmune myocarditis¹⁵⁵. In a type 1 diabetic cardiomyopathy model, chronic cannabidiol treatment attenuated diabetes-induced myocardial dysfunction, cardiac fibrosis, oxidative and nitritative stress, inflammation, cell death, and inter-related signalling pathways¹⁵⁴. Moreover, cannabidiol in human primary cardiomyocytes attenuated the high glucose-induced nuclear factor- κ B activation, generation of reactive oxygen species, and cell death¹⁵⁴. In doxorubicin-induced cardiomyopathy, cannabidiol markedly improved cardiac dysfunction, oxidative and nitritative stress, and cell death, and reversed the impaired cardiac mitochondrial function and biogenesis¹⁵². Chronic cannabidiol treatment in a mouse model of autoimmune myocarditis improved cardiac dysfunction, decreased the CD3⁺ and CD4⁺ cell-mediated inflammatory response and injury, and myocardial fibrosis¹⁵⁵. These results, coupled with the known safety of cannabidiol in humans¹⁵⁶ and its efficacy for treatment of rare forms of treatment-resistant childhood epilepsy (Dravet syndrome and Lennox–Gastaut syndrome)^{157–159}, might open a new avenue to test cannabidiol in multiple cardiovascular disorders¹⁵⁹. Preliminary results of clinical trials with cannabidiol in graft-versus-host disease are also encouraging¹⁶⁰.

Tetrahydrocannabinarin is another constituent of marijuana with potential medical benefits. Tetrahydrocannabinarin was reported to be a CB₁R antagonist at a low dose, but a CB₁R agonist at a high dose, as well as a CB₂R partial agonist, and produced relevant beneficial metabolic effects in preclinical disease models of obesity and steatohepatitis^{161,162}. Tetrahydrocannabinarin was safe in a phase II clinical study^{163,164}. Various other minor cannabinoids and terpenoids contained in cannabis (such as β -caryophyllene) can also exert important biological effects, which could be exploited for therapeutic benefit¹⁶⁵.

Of note, THC is not only a fairly weak partial CB₁R agonist, but also a CB₂R agonist, and might have additional anti-inflammatory and antioxidant effects, independent of CB₂R. Therefore, at very low doses THC might not elicit substantial CB₁R activation, which underlies the majority of its cardiovascular adverse effects, and might even exert some anti-inflammatory effects. For example, as previously mentioned, low doses of THC attenuated atherosclerosis and vascular inflammation in mice in a CB₂R-dependent manner⁸⁸. By contrast, at higher doses, THC was ineffective, possibly because of pro-inflammatory effects caused by CB₁R activation.

Interestingly, Waldman and colleagues described that a single, ultralow dose (three to four orders of magnitude lower than the conventional doses) of THC given before myocardial infarction in mice exerted cardioprotective effects¹⁶⁶. The involvement of cannabinoid receptors in the cardioprotection observed was not evaluated¹⁶⁶. Chronic THC administration was previously reported to downregulate CB₁R dose-dependently

in particular neurons of the brain¹⁶⁷. A subsequent study surprisingly found that chronic administration of THC at a low dose improved cognitive function in ageing, but not young, mice via CB₁R-dependent mechanisms¹⁶⁸. In young to middle-aged humans, cannabis use dose-dependently impairs learning and memory, and can also trigger psychosis in susceptible individuals¹⁷. With the markedly increased use of cannabis among the older US population¹⁶⁹, further research is warranted to investigate the cognitive and cardiovascular effects of marijuana in the ageing population.

Interestingly, an epidemiological study using a quantile regression approach based on National Health and Nutrition Examination Surveys (NHANES 2005–2010, encompassing participants aged 20–59 years; $n = 1,115$ recently active cannabis smokers and 8,041 nonsmokers, identified via confidential audio computer-assisted self-interviews) concluded that cannabis smoking might be associated with reduced serum levels of C-reactive protein¹⁷⁰. Analysis of NHANES 1988–1994 data also indicated that marijuana use was independently associated with a lower prevalence of diabetes mellitus¹⁷¹. Another study found no changes in insulin sensitivity and glucose tolerance in chronic marijuana smokers¹⁷². These findings are in contrast to the THC-induced acute insulin resistance¹⁷³ and glucose intolerance in drug-naïve individuals, and the documented efficacy of chronic CB₁R antagonism in improving visceral obesity and its complications, including insulin resistance and type 2 diabetes in both humans and experimental animals¹⁷⁴. This apparent contradiction might be reconciled by the known capacity of THC to cause profound and long-lasting downregulation of CB₁R at doses producing plasma levels similar to those in heavy users^{106,108,110–113,115,117,167,175}.

Further clinical studies are clearly needed to determine the effects of acute and chronic marijuana use on inflammation and glycaemic control. One major limitation of epidemiological studies on marijuana is the uncertainty about the composition of the marijuana used by the surveyed individuals (THC content, THC–cannabidiol ratio) that might result in diverse, even opposing, cardiovascular consequences.

Adverse effects

Heart rate and blood pressure. Depending on the dose, frequency, route of administration, and duration of use, marijuana or its active constituent THC can have diverse effects on heart rate and blood pressure, both in experimental animals and in humans^{8,17}. The most common acute effect in healthy volunteers is increase in heart rate and decrease in blood pressure, depending on dose, route of administration, and the individual. The synthetic THC (dronabinol or Marinol; AbbVie, USA) and its analogue nabilone (Cesamet; Meda Pharmaceuticals, USA), approved by the FDA for chemotherapy-induced nausea and vomiting and stimulation of appetite in AIDS-induced cachexia, and also approved in Canada for management of chronic pain, similarly elicited dose-dependent increases in heart rate and decreases in blood pressure¹⁷⁶.




Figure 2 | Reported cardiovascular adverse consequences of recreational marijuana and synthetic cannabinoid use. *Adverse effects that were reported for synthetic cannabinoids; note almost complete overlap with the adverse effects of marijuana.

Several studies investigated the development of tolerance to the psychoactive and cardiovascular effects of THC or marijuana and their dependence on CB₁R. Gorelick and colleagues reported the development of tolerance to the subjective intoxication, but not to the tachycardia and hypotension induced by a high oral dose of synthetic THC taken daily for 6–13 days by healthy marijuana users¹⁷⁷. All these effects or the similar effects of smoked marijuana were antagonized by single or multiple doses of rimonabant^{178–180}. Similarly, the central nervous system and cardiac effects of inhaled THC were inhibited by surinabant, another selective CB₁R antagonist¹⁸¹.

The demonstration of an important role for peripheral CB₁R in pain¹⁸² was the rationale for the development of peripherally-restricted CB₁R agonists as analgesics devoid of psychoactive effects, such as the peripherally restricted, orally active mixed CB₁R/CB₂R agonists AZD1940 and AZD1704, introduced by AstraZeneca for the treatment of pain^{183,184}. However, in clinical trials in healthy volunteers, peripheral CB₁R agonism was associated with adverse cardiovascular and metabolic effects, including weight gain, hypotension, heart rate abnormalities, and mild hepatotoxicity, which ultimately led to the termination of the study and dismissal of peripheral CB₁R as a potential therapeutic target for pain^{183,184}.

Vascular disease and myocardial infarction. The studies described above, using fairly low doses of THC or marijuana with low THC content in healthy volunteers, provided proof that, similar to their effects in rodents, the acute cardiovascular effects of marijuana and THC are indeed mediated by CB₁R in the cardiovascular system. In parallel with the dramatic increase in the THC content of marijuana, a growing number of case reports and clinical studies associate recreational marijuana use

with adverse cardiovascular consequences ranging from acute coronary syndrome^{185–188}; coronary thrombosis¹⁸⁹; myocardial infarction^{185,190–196}; cardiomyopathies^{197–199}; heart failure²⁰⁰; stroke^{185,200}; vasospasm, vascular inflammation, or artery dissection^{185,201}; arrhythmias (atrial fibrillation^{202–204}, atrioventricular block^{205,206}, ventricular tachycardia or fibrillation^{207,208}, asystole²⁰⁹), and sudden death²¹⁰ (FIG. 2). Mittleman and colleagues assessed the risk of acute myocardial infarction in 124 marijuana smokers (37 were smoking marijuana within 24 h of myocardial infarction) in a cohort of 3,882 patients in the MI Onset Study¹⁹¹. Marijuana smokers had a 4.8-fold higher risk of developing acute myocardial infarction during the first hour of exposure, with a rapidly declining risk thereafter¹⁹¹. A longitudinal, prospective follow-up study involving 1,913 adults (52 reported marijuana use during the previous year) hospitalized with myocardial infarction at 45 US hospitals between 1989 and 1994 with a median follow-up of 3.8 years, evaluated the effect of marijuana on mortality after acute myocardial infarction¹⁹⁶. Cannabis use less than once per week was associated with 2.5-fold increased risk of dying¹⁹⁶. This risk was further exacerbated by more frequent marijuana use, yielding up to fourfold elevated risk¹⁹⁶. The investigators concluded that marijuana use might particularly increase the risk of infarction in susceptible individuals with coronary heart disease¹⁹⁶. The study was also followed up 5 years later to evaluate the consequences of marijuana use on long-term mortality among survivors of acute myocardial infarction¹⁹². During follow-up (up to 18 years), 519 patients died, including 22 of the 109 reported marijuana users¹⁹². Habitual marijuana use was associated with a nonsignificant 29% increase in mortality over the ensuing 18 years¹⁹².

Jouanous and colleagues analysed all cardiovascular complications related to cannabis use based on reports from 2006 to 2010 in the French Addictovigilance Network¹⁸⁵. They found that in 35 out of 1,979 cannabis-related reports, 30 men with an average age of 34 years had cardiovascular complications, including 20 cases of acute coronary syndrome, 10 cases of peripheral vascular complications (lower limb or juvenile arteriopathies and Buerger-like diseases), and three cases of cerebral complications (acute cerebral angiopathy, transient cortical blindness, and cerebral artery vasospasm). The results of this study were striking not only because they involved fairly young individuals with no prior cardiovascular disease, but also because 25.6% of the affected patients (nine individuals) died from the cardiovascular complications of cannabis use¹⁸⁵. An increasing number of case reports describing severe cardiovascular complications of marijuana use in young individuals (including previously unreported fatalities)^{185–187,189,190,198,201,203,204,209,210} support the conclusions of the French study, thus raising serious concerns about the cardiovascular safety of marijuana use. Reis and colleagues investigated the effects of marijuana on the development of incident cardiovascular and cerebrovascular outcomes based on data from the CARDIA study²¹¹ in 4,286 adults aged 18–30 years in 1985–1986 and who reported a history of marijuana use. The researchers found that neither

recent use of marijuana nor cumulative lifetime use was associated with increased incidence of cardiovascular disease²¹¹. By contrast, Draz and colleagues conducted a cross-sectional study performed on 138 male patients (23 positive for cannabis) aged <40 years with acute myocardial infarction, and concluded that cannabis smoking was a potential risk factor for the development of cardiac ischaemia¹⁸⁷. A retrospective study presented at the AHA Scientific Sessions in 2016 suggested that active marijuana use doubles the risk of Takotsubo cardiomyopathy, especially in young men¹⁹⁹. Kalla and colleagues performed the most comprehensive analysis of health records to date, based on the Nationwide Inpatient Sample 2009–2010 database of individuals aged 18–55 years with a history of cannabis use (presented at the ACC Scientific Sessions in 2017). Demographics, risk factors, and cardiovascular event rates were collected on these patients and compared with general population data. They identified 316,397 (1.5%) cannabis users and 20,499,215 (98.5%) nonusers in the database, and found that the incident of cerebrovascular accidents, heart failure, coronary artery disease, sudden cardiac death, and hypertension were significantly higher in patients with cannabis use. After multivariate regression analysis adjusting for age, sex, diabetes, hypertension, coronary artery disease, and tobacco and alcohol use, cannabis use remained an independent predictor of both heart failure and cerebrovascular accidents²⁰⁰.

Stroke. Several studies have investigated the association between stroke and marijuana use. Falkstedt and colleagues used a population-based cohort of 49,321 Swedish men, born between 1949 and 1951, who were in military service between the ages of 18 and 20 years, to investigate the association between cannabis use and early-onset stroke, when accounting for the use of tobacco and alcohol²¹². Although they found an almost doubled risk of ischaemic stroke in those with cannabis use >50 times, this risk was no longer significant when adjusted for tobacco usage, which by itself showed dose-dependent association with stroke²¹². Di Napoli and colleagues analysed an international, multicentre, observational database of 725 patients with spontaneous ischaemic stroke, 8.6% of whom were positive for cannabinoids, and found no relationship between cannabis use and specific ischaemic stroke characteristics²¹³. Surprisingly, cannabinoid use was associated with milder ischaemic stroke presentation and less disability at discharge from hospital²¹³.

Rumalia and colleagues investigated the relationship between marijuana use and hospitalization for acute ischaemic stroke²¹⁴ and for aneurysmal subarachnoid haemorrhage²¹⁵ using the Nationwide Inpatient Sample from 2004 to 2011. They found that among younger adults (aged 25–34 years), recreational marijuana use was independently associated with a 17% increased likelihood of hospitalization for acute ischaemic stroke and with an 18% increased likelihood of hospitalization for aneurysmal subarachnoid haemorrhage. Behrouz and colleagues evaluated the relationship between cannabis use and outcomes in patients with

aneurysmal subarachnoid haemorrhage, analysing the records of 108 patients, 25.9% of whom were positive for urine cannabinoids. Their preliminary data implied an independent association between cannabis use (positive urine) and delayed cerebral ischaemia and possibly poor outcome in patients with subarachnoid haemorrhage²¹⁶. Hemachandra and colleagues examined the risk of non-fatal stroke or transient ischaemic attack among cannabis users in the general Australian community²¹⁷. In a cohort of 153 patients with stroke or transient ischaemic attack, individuals who had used cannabis in the past year had a 3.3-fold higher event rate than nonusers after adjusting for age, or a 2.3-fold higher rate than nonusers after further adjustment for covariates related to stroke, including tobacco smoking. This increased risk was specific to participants who used cannabis weekly or more often²¹⁷, suggesting that heavy cannabis users in the general community have a higher rate of nonfatal stroke or transient ischaemic attack than low-frequency users or nonusers of cannabis²¹⁷. An analysis of 29 studies suggesting an association between exposure to cannabis-based products and cardiovascular disease concluded that the evidence is stronger for an association with ischaemic strokes than for any other cardiovascular diseases, although evidence indicates that cannabis use can have negative cardiovascular consequences, particularly at high doses²¹⁸.

Wolff and Jouanous analysed 98 cases of cannabinoid-related strokes (85 of which followed marijuana use and 13 of which followed synthetic cannabinoid use) in young adults (mean age 32.3 years; 73% men)²¹⁹. Overall, 81% of patients with cannabinoid-related strokes were chronic cannabis users and in two-thirds of the patients, cannabis was smoked with tobacco. The researchers found that 87% of the reported strokes were ischaemic and/or a transient ischaemic attack, and 8.1% were haemorrhagic²¹⁹. Despite a favourable outcome in almost half of the patients, five (5.1%) died²¹⁹. The investigators noted a strong temporal correlation in the majority of the reports between cannabinoid use (natural or synthetic) and the occurrence of stroke²¹⁹. They also speculated that enhanced generation of reactive oxygen species induced by cannabinoids, and consequent oxidative stress (a known mechanism of stroke in humans) might be an underlying pathological mechanism²¹⁹. This hypothesis is in agreement with the previously described increased, CB₁R-dependent generation of reactive oxygen species in human and mouse cardiomyocytes, coronary artery endothelial and vascular smooth muscle cells, macrophages, and podocytes^{41,42,47,101,220,221} (BOX 1). Increased superoxide in the vasculature immediately reacts with nitric oxide to form a reactive oxidant and nitrating species peroxynitrite via diffusion-limited reaction, which also uncouples nitric oxide synthases²²². The resulting rapidly decreased nitric oxide bioavailability can lead to endothelial dysfunction, functional hypoxia, and/or vasospasm²²². In susceptible individuals, the cannabinoid-induced marked CB₁R-mediated vasodilatation and drop in total peripheral resistance with consequent profound and prolonged hypotension might also precipitate ischaemic stroke.

A retrospective follow-up study of 1,213 NHANES participants (21% of whom used marijuana only, 20% marijuana and cigarettes, and 16% marijuana and were past smokers) investigated the associations between marijuana use (average duration 11.5 years) and death from hypertension, heart disease, or cerebrovascular disease, controlling for cigarette use and demographic variables including sex, age, and ethnicity²²³. Surprisingly, the investigators found that marijuana users had a 3.42-fold increased risk of death from hypertension, with a 1.04-fold greater risk for each year of use. However, no association between marijuana use and death from heart disease or cerebrovascular disease was established.

Effects of marijuana smoke. Marijuana smoke (like tobacco smoke) is harmful and can exert adverse cardiovascular effects independent from cannabinoid receptors. For example, one study demonstrated that 1 min of exposure to marijuana second-hand smoke impaired femoral artery flow-mediated dilatation to a similar extent as caused by equal concentrations of tobacco second-hand smoke, but recovery was considerably slower for marijuana²²⁴. The investigators found that exposure to marijuana second-hand smoke directly caused cannabinoid-independent vasodilatation that subsided within 25 min, whereas flow-mediated dilatation remained impaired for ≥ 90 min in rats. Impairment occurred even when marijuana lacked cannabinoids, suggesting that impairment of flow-mediated vasodilatation does not require cannabinoids or nicotine²²⁴. As with tobacco smoke, marijuana can also increase carboxyhaemoglobin levels, independent from cannabinoid receptors, resulting in decreased oxygen-carrying capacity¹⁹¹. The increased heart rate after acute marijuana smoking peaked 10–30 min after the beginning of smoke exposure, and probably resulted from compensatory sympathetic activation, in response to the THC-induced, CB₁R-mediated decrease in total peripheral resistance and blood pressure. Of note, these acute cardiovascular effects of marijuana or THC in humans were almost completely prevented or reversed by two different CB₁R antagonists (as discussed earlier). Nevertheless, in susceptible individuals, acute marijuana smoking might be associated with a transient increase in myocardial oxygen demand paralleled by a decrease in oxygen supply¹⁹¹, promoting a situation favouring the development of myocardial ischaemia and infarction, particularly if the cardiac reserve capacity is decreased.

Mortality. In the absence of large-scale, long-term, controlled studies (known marijuana composition, route, dose, and frequency of administration) with repeated measures of marijuana use, one cannot draw a firm conclusion on the long-term effect of cannabis use on cardiovascular mortality. However, marijuana (presumably with increased THC content) can induce dangerous, often life-threatening cardiovascular effects, probably mediated by the activation of CB₁R. The use of synthetic ‘designer’ CB₁R agonist mixtures (spice variants) with greatly increased potency at CB₁R compared with THC, is likely to increase the levels of cardiovascular morbidity.

Synthetic cannabinoids

These ‘seemingly innocent, herbal products’, many of which are not controlled and are easily available online or in grocery stores, could be far more dangerous than THC in marijuana used for recreational purpose^{225–239}. As with marijuana, the route of administration of synthetic cannabinoids can importantly influence their biological, including cardiovascular, effects.

Mir and colleagues described three cases of acute myocardial infarction in boys aged 16 years after smoking K2 or spice, who presented in the emergency department 1 day after K2 use complaining about chest pain. Myocardial infarction was diagnosed by electrocardiogram and myocardial enzymes²²⁵. At that time, K2 or spice contained mainly JWH-018, JWH-073, and similar derivatives²²⁵. Subsequent cases of cardiac arrest, myocardial infarction, and fatal toxicities were also described after K2 use in young teenagers or young adults^{226–230}. Orsini and colleagues described a case of acute hypoxaemic/hypercapnic respiratory failure as a consequence of acute congestive heart failure developed from myocardial stunning, which was the result of myocardial infarction without ST-segment elevation²³¹. Two cases of synthetic cannabinoid ‘bonsai’-induced cardiovascular adverse effects were described in individuals aged 16 and 18 years, consistent with AMI²³².

Obafemi and colleagues reported on 11 symptomatic patients aged 20–57 years, who unknowingly ingested brownies laced with analytically confirmed synthetic CB₁R agonists, including AM-2201 (REF. 233). Neuropsychiatric and cardiovascular symptoms were predominant (memory impairment, blurring of vision, facial numbness, increased heart rate, and/or increased blood pressure). All patients were discharged within 10 h in a stable condition²³³. A retrospective analysis of 22 patients aged 12–25 years, presenting to emergency departments with analytically confirmed intake of JWH-210 from a poison centre database from March 2011 to June 2014, evaluated the most common cardiovascular and central nervous system adverse consequences, which ranged from restlessness, agitation, tachycardia, nausea, somnolence, and hypertension, to syncope, T-wave inversion on the electrocardiogram, and bradycardia²³⁴. Of note, in 80% of the patients, the adverse changes in heart rate and blood pressure were accompanied by electrocardiogram abnormalities²³⁴. Hill and colleagues described seven patients who were hospitalized because of synthetic cannabinoid MDMB-CHMICA-related toxicity in England, featuring respiratory, metabolic, or mixed acidosis; reduced level of consciousness; tachycardia or bradycardia; convulsions; and agitation²³⁵.

Monte and colleagues aimed to determine the clinical characteristics of patients abusing synthetic cannabinoids in a multicentre analysis of a prospective cohort of patients between 2010 and 2015 who presented for medical care after inhalation of synthetic cannabinoids. The researchers identified 353 cases out of 39,925 hospital visits that involved synthetic cannabinoid-related toxicity. The most common symptoms were agitation, delirium or psychosis, and increased or decreased heart rate often reaching < 50 bpm (REF. 236). In some patients,

seizures also developed²³⁶. The investigators concluded that synthetic cannabinoids were associated with severe central nervous system and cardiovascular effects²³⁶.

The Emergency Department at Lincoln Medical Center, New York, USA, noted changes in symptoms in K2 abusers during an outbreak in the summer of 2015. These changes included marked bradycardia and hypotension while maintaining global neurological function²³⁷. Alarming, synthetic cannabinoid-related mortality is also rising with the introduction of extremely potent variants of spice in 2014–2015, which also caused cluster toxicities^{6,230}.

FIGURE 3 shows the dramatic cardiovascular effects after intravenous administration to rats of the potent synthetic cannabinoid CB₁R agonist HU210, which is also used in spice variants. HU210 caused a rapid decrease in cardiac performance (left ventricular pressure, left ventricular contractility, and shift of pressure–volume loops to the right) and blood pressure, which could be almost completely reversed by an acute dose of CB₁R antagonist SR141716 (rimonabant). This finding, coupled with the previously discussed evidence on the rapid reversibility of all cardiovascular effects of THC or marijuana in healthy volunteers, strongly suggests that rimonabant could be repurposed and used as an antidote in cases of acute toxicity caused by marijuana or synthetic cannabinoids.

Synthetic cannabinoids have also been reported to cause severe acute and chronic kidney injury in children and young adults, and the CDC has issued a warning^{238,239}. These nephrotoxic effects of synthetic cannabinoids are not surprising given the important role of CB₁R in promoting both glomerular and tubular injury in preclinical models of acute and chronic kidney disorders, in which CB₁R inhibition or deletion has beneficial effects^{221,240–243}.

Conclusions

Both preclinical and clinical evidence supports the involvement of the endocannabinoid–CB₁R system in obesity, metabolic syndrome, and diabetes, and the associated cardiovascular risk (such as abdominal obesity, plasma lipid alterations, hepatic steatosis, and leptin and insulin resistance). This signalling system has also been implicated in the development and progression of various forms of shock, cardiovascular collapse, cardiomyopathies, heart failure, atherosclerosis, and restenosis, where peripherally restricted CB₁R antagonists could be beneficial without causing central nervous system-mediated neuropsychiatric adverse effects, which halted the therapeutic development of globally acting CB₁R antagonists.

Accumulating evidence also supports the development of selective CB₂R agonists for the management of




Figure 3 | Adverse cardiovascular consequences of synthetic cannabinoids. Cardiovascular effects of potent synthetic cannabinoid receptor 1 (CB₁R) agonist HU210. Intravenous administration of HU210 (0.1 mg/kg) to a rat dramatically decreases left ventricular (LV) pressure (blue trace), LV contractility (+dp/dt; green trace), and blood pressure (purple trace), and shifts pressure–volume loops to the right, indicating decreased cardiac performance. After injection of a CB₁R antagonist, SR141716 (rimonabant; 10 mg/kg), cardiac function and blood pressure largely recover within 20 mins. Reprinted with permission from Pacher, P. *et al.* Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. *Nat. Protoc.* 3 (9), 1422–1434 (2008), with permission from Macmillan Publishers Limited.

Table 1 | Cardiovascular effects of endocannabinoids, marijuana, and synthetic cannabinoids

Substance	Good	Bad	Ugly
Endocannabinoids	<ul style="list-style-type: none"> • CB₂R-mediated tissue-protective and anti-inflammatory effects • Potential source of anti-inflammatory and beneficial vasoactive mediators via metabolism to arachidonic acid 	<ul style="list-style-type: none"> • CB₁R-mediated metabolic, cardiovascular, pro-inflammatory, pro-oxidant, and profibrotic effects • Potential source of pro-inflammatory mediators via metabolism to arachidonic acid or oxidation by cyclooxygenase 	<ul style="list-style-type: none"> • Potential source of vasoconstrictor mediators (for example, thromboxane A₂) via metabolism to arachidonic acid or oxidation by cyclooxygenase
Marijuana (partial agonist)	<ul style="list-style-type: none"> • Low dose of THC in marijuana might exert CB₂R-mediated and unrelated tissue-protective and anti-inflammatory effects • THC is a fairly weak partial CB₁R agonist; therefore, the acute cardiovascular and CNS effects are often mild and reversible • Marijuana can contain various nonpsychoactive constituents that do not activate CB₁R and might exert beneficial anti-inflammatory and antioxidant effects (for example, cannabidiol, tetrahydrocannabinavarin, terpenoids, β-caryophyllene) 	<ul style="list-style-type: none"> • THC can exert CB₁R-mediated metabolic, cardiovascular, pro-inflammatory, pro-oxidant, and profibrotic effects (the cardiovascular effects are dose-dependent) • THC exerts CB₁R-mediated psychoactive effects • Marijuana smoke can be as harmful as tobacco smoke • Marijuana can accumulate pesticides and heavy metals 	<ul style="list-style-type: none"> • In rare cases, life-threatening cardiovascular effects can develop (for example, arrhythmias, profound hypotension, myocardial infarction, ischaemic stroke)
Synthetic cannabinoids (for example, spice); commonly a mixture of very potent and efficacious CB ₁ R agonists (some several hundred times more potent than THC) with long half-lives	NA	NA	<ul style="list-style-type: none"> • Can induce very severe and fatal cardiovascular, CNS, and kidney complications, also very addictive • Can contain organic solvents (masking mass spectrometry detection) and other unknown drugs

CB₁R, cannabinoid receptor 1; CB₂R, cannabinoid receptor 2; CNS, central nervous system; NA, not applicable; THC, Δ^9 -tetrahydrocannabinol.

acute tissue injury associated with inflammation (such as myocardial infarction, stroke, or organ transplantation). Therapeutic targeting of the endocannabinoid-degrading enzymes FAAH and MGL can be a double-edged sword owing to amplification of not only therapeutically desirable, but also adverse endocannabinoid effects, indicating the need for further research.

The clinical indication for marijuana or marijuana-based products (such as extracts, synthetic THC, or analogues: dronabinol, nabilone, and nabiximols) is still very limited and includes chemotherapy-induced nausea and vomiting, and promotion of appetite in wasting disorders such as AIDS or tumour cachexia. Although these indications might be expanded to include various forms of chronic pain, evidence so far suggests that these drugs are not sufficiently effective on objective measures or scales of pain in controlled clinical trials, even though they are effective by many subjective measures.

Despite a dearth of evidence for a substantial cardiovascular risk of marijuana use until the past few years, evidence now indicates an alarming rise in the incidence of severe and sometimes fatal cardiovascular adverse effects, which has paralleled the dramatic increase in the THC content of recreational marijuana as well as the appearance of a variety of synthetic or 'designer' cannabinoids, whose potency and efficacy far exceed those of THC. These warning signs cannot be ignored and have to be further studied to assess their public-health implications.

The efficacy and probable approval of cannabidiol for therapeutic use in treatment-resistant epilepsy is exciting, and might open a new avenue for exploratory clinical trials in other diseases, including diabetes and

diabetic complications, graft-versus-host disease, and cardiovascular diseases in which preclinical data support the therapeutic potential of cannabidiol. To this end, limiting or even eliminating THC from cannabis extracts used in the management of such disorders would make sense.

We are in the era of widespread legalization of marijuana for medicinal, and even recreational, use. We can also download hundreds of marijuana-related applications to our phone to pick our favourite marijuana varieties or learn how to start a marijuana business, which is growing into a multibillion industry. The medicinal use of marijuana and its constituents is likely to lead to important therapeutic opportunities to ease human suffering. These opportunities might be risked by ignoring the clear and present danger posed by the spread of marijuana containing high levels of THC, and designer drugs containing superpotent synthetic cannabinoids, which have been linked to severe cardiovascular, kidney, and central nervous system toxicity. Given the clustering of cannabis-related toxicity in multiple states, the repurposing of rimonabant as an antidote for such poisonings should be seriously considered. Physicians should also be very vigilant to recognizing these effects and their underlying cause. TABLE 1 summarizes the effects of endocannabinoids, marijuana, and synthetic cannabinoids relevant to cardiovascular outcomes and pathology. Further research is warranted to inform the regulatory measures that are needed to curb the spread of synthetic cannabinoids and to keep the risk–benefit ratio of the medicinal use of marijuana and related cannabinoids as low as possible.

1. World Health Organization. The health and social effects of nonmedical cannabis use. *WHO* http://www.who.int/substance_abuse/publications/msbcannabis.pdf (2016).
2. NewFrontier data. The cannabis industry annual report: 2017 legal marijuana outlook. *NewFrontier data* <https://newfrontierdata.com/annualreport2017/> (2017).
3. United Nations Office on Drugs and Crime. Synthetic cannabinoids: key facts about the largest and most dynamic group of NPS. *UNODC* https://www.unodc.org/documents/scientific/Global_SMART_Update_13_web.pdf (2015).
4. Banister, S. D. *et al.* Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. *ACS Chem. Neurosci.* **6**, 1546–1559 (2015).
5. Adams, A. J. *et al.* “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. *N. Engl. J. Med.* **376**, 235–242 (2017).
6. Kasper, A. M. *et al.* Severe illness associated with reported use of synthetic cannabinoids — Mississippi, April 2015. *MMWR Morb. Mortal. Wkly Rep.* **64**, 1121–1122 (2015).
7. Law, R. *et al.* Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use — United States, January–May 2015. *MMWR Morb. Mortal. Wkly Rep.* **64**, 618–619 (2015).
8. Pachter, P. *et al.* Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. *Hypertension* **52**, 601–607 (2008).
9. Pachter, P. & Hasko, G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. *Br. J. Pharmacol.* **153**, 252–262 (2008).
10. Steffens, S. & Pachter, P. Targeting cannabinoid receptor CB₂ in cardiovascular disorders: promises and controversies. *Br. J. Pharmacol.* **167**, 313–323 (2012).
11. Montecucco, F. & Di Marzo, V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. *Trends Pharmacol. Sci.* **33**, 331–340 (2012).
12. Steffens, S. & Pachter, P. The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism? *Curr. Drug Targets* **16**, 334–341 (2015).
13. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* **346**, 561–564 (1990).
14. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature* **365**, 61–65 (1993).
15. Devane, W. A. *et al.* Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **258**, 1946–1949 (1992).
16. Pertwee, R. G. *et al.* International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. *Pharmacol. Rev.* **62**, 588–631 (2010).
17. Pachter, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* **58**, 389–462 (2006).
18. Kunos, G. & Tam, J. The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. *Br. J. Pharmacol.* **163**, 1423–1431 (2011).
19. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? *Nat. Rev. Drug Discov.* **7**, 438–455 (2008).
20. Pachter, P. & Mechoulam, R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? *Prog. Lipid Res.* **50**, 193–211 (2011).
21. Howlett, A. C. *et al.* International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.* **54**, 161–202 (2002).
22. Soethoudt, M. *et al.* Cannabinoid CB₂ receptor ligand profiling reveals biased signalling and off-target activity. *Nat. Commun.* **8**, 13958 (2017).
23. Delgado-Peraza, F. *et al.* Mechanisms of biased beta-arrestin-mediated signaling downstream from the cannabinoid 1 receptor. *Mol. Pharmacol.* **89**, 618–629 (2016).
24. Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. *J. Biol. Chem.* **279**, 5298–5305 (2004).
25. Liu, J. *et al.* Multiple pathways involved in the biosynthesis of anandamide. *Neuropharmacology* **54**, 1–7 (2008).
26. Simon, G. M. & Cravatt, B. F. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. *J. Biol. Chem.* **283**, 9341–9349 (2008).
27. Gao, Y. *et al.* Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. *J. Neurosci.* **30**, 2017–2024 (2010).
28. Tanimura, A. *et al.* The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. *Neuron* **65**, 320–327 (2010).
29. Hsu, K. L. *et al.* DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses. *Nat. Chem. Biol.* **8**, 999–1007 (2012).
30. Willoughby, K. A., Moore, S. F., Martin, B. R. & Ellis, E. F. The biosynthesis and metabolism of anandamide in mice. *J. Pharmacol. Exp. Ther.* **282**, 243–247 (1997).
31. Cravatt, B. F. *et al.* Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc. Natl Acad. Sci. USA* **98**, 9371–9376 (2001).
32. Dinh, T. P. *et al.* Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc. Natl Acad. Sci. USA* **99**, 10819–10824 (2002).
33. Yu, M., Ives, D. & Ramesha, C. S. Synthesis of prostaglandin E₂ ethanolamide from anandamide by cyclooxygenase-2. *J. Biol. Chem.* **272**, 21181–21186 (1997).
34. Kozak, K. R., Rowlinson, S. W. & Marnett, L. J. Oxygenation of the endocannabinoid, 2-arachidonoylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. *J. Biol. Chem.* **275**, 33744–33749 (2000).
35. Ueda, N., Tsuboi, K. & Uyama, T. Metabolism of endocannabinoids and related N-acyl ethanolamines: canonical and alternative pathways. *FEBS Lett.* **280**, 1874–1894 (2013).
36. Wang, J. & Ueda, N. Biology of endocannabinoid synthesis system. *Prostaglandins Other Lipid Mediat.* **89**, 112–119 (2009).
37. Piscitelli, F. & Di Marzo, V. “Redundancy” of endocannabinoid inactivation: new challenges and opportunities for pain control. *ACS Chem. Neurosci.* **3**, 356–363 (2012).
38. Bonz, A. *et al.* Cannabinoids acting on CB₁ receptors decrease contractile performance in human atrial muscle. *J. Cardiovasc. Pharmacol.* **41**, 657–664 (2003).
39. Batkai, S. *et al.* Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. *Circulation* **110**, 1996–2002 (2004).
40. Montecucco, F. *et al.* CB₂ cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. *J. Mol. Cell. Cardiol.* **46**, 612–620 (2009).
41. Rajesh, M. *et al.* Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. *Diabetes* **61**, 716–727 (2012).
42. Mukhopadhyay, P. *et al.* CB₁ cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. *Cardiovasc. Res.* **85**, 773–784 (2010).
43. Mukhopadhyay, P. *et al.* Pharmacological inhibition of CB₁ cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. *J. Am. Coll. Cardiol.* **50**, 528–536 (2007).
44. Sugiura, T. *et al.* Detection of an endogenous cannabinimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB₁ receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? *Biochem. Biophys. Res. Commun.* **243**, 838–843 (1998).
45. Deutsch, D. G. *et al.* Production and physiological actions of anandamide in the vasculature of the rat kidney. *J. Clin. Invest.* **100**, 1538–1546 (1997).
46. Rajesh, M., Mukhopadhyay, P., Hasko, G. & Pachter, P. Cannabinoid CB₁ receptor inhibition decreases vascular smooth muscle migration and proliferation. *Biochem. Biophys. Res. Commun.* **377**, 1248–1252 (2008).
47. Rajesh, M. *et al.* Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. *Br. J. Pharmacol.* **160**, 688–700 (2010).
48. Galiegue, S. *et al.* Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur. J. Biochem.* **232**, 54–61 (1995).
49. Hohmann, A. G. & Herkenham, M. Localization of central cannabinoid CB₁ receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label *in situ* hybridization study. *Neuroscience* **90**, 923–931 (1999).
50. Niederhoffer, N., Schmid, K. & Szabo, B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. *Naunyn-Schmiedeberg Arch. Pharmacol.* **367**, 434–443 (2003).
51. Burdya, G. *et al.* Expression of cannabinoid CB₁ receptors by vagal afferent neurons is inhibited by cholecystokinin. *J. Neurosci.* **24**, 2708–2715 (2004).
52. Wenzel, D. *et al.* Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction. *Proc. Natl Acad. Sci. USA* **110**, 18710–18715 (2013).
53. Prescott, S. M. & Majerus, P. W. Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. *J. Biol. Chem.* **258**, 764–769 (1983).
54. Batkai, S. *et al.* Endocannabinoids acting at vascular CB₁ receptors mediate the vasodilated state in advanced liver cirrhosis. *Nat. Med.* **7**, 827–832 (2001).
55. Wagner, J. A. *et al.* Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. *J. Am. Coll. Cardiol.* **38**, 2048–2054 (2001).
56. Chirchicu, V. *et al.* Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. *Atherosclerosis* **233**, 55–63 (2014).
57. Maccarrone, M. *et al.* Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. *Arch. Biochem. Biophys.* **393**, 321–328 (2001).
58. Matias, I. *et al.* Presence and regulation of the endocannabinoid system in human dendritic cells. *Eur. J. Biochem.* **269**, 3771–3778 (2002).
59. Maccarrone, M., Bari, M., Menichelli, A., Del Principe, D. & Agro, A. F. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. *FEBS Lett.* **447**, 277–282 (1999).
60. Chouinard, F. *et al.* The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: critical role of its hydrolysis and *de novo* leukotriene B₄ biosynthesis. *J. Immunol.* **186**, 3188–3196 (2011).
61. Randall, M. D. *et al.* An endogenous cannabinoid as an endothelium-derived vasorelaxant. *Biochem. Biophys. Res. Commun.* **229**, 114–120 (1996).
62. Molica, F. *et al.* Endogenous cannabinoid receptor CB₁ activation promotes vascular smooth-muscle cell proliferation and neointima formation. *J. Lipid Res.* **54**, 1360–1368 (2013).
63. Molica, F. *et al.* Cannabinoid receptor CB₂ protects against balloon-induced neointima formation. *Am. J. Physiol. Heart Circ. Physiol.* **302**, H1064–H1074 (2012).
64. Rajesh, M. *et al.* CB₂ cannabinoid receptor agonists attenuate TNF-α-induced human vascular smooth muscle cell proliferation and migration. *Br. J. Pharmacol.* **153**, 347–357 (2008).
65. Pachter, P., Batkai, S. & Kunos, G. Cardiovascular pharmacology of cannabinoids. *Handb. Exp. Pharmacol.* 599–625 (2005).
66. Stanley, C. & O’Sullivan, S. E. Vascular targets for cannabinoids: animal and human studies. *Br. J. Pharmacol.* **171**, 1361–1378 (2014).
67. Benyo, Z., Ruisanchez, E., Leszl-Ishiguro, M., Sandoz, P. & Pachter, P. Endocannabinoids in cerebrovascular regulation. *Am. J. Physiol. Heart Circ. Physiol.* **310**, H785–H801 (2016).
68. Liu, J. *et al.* Functional CB₁ cannabinoid receptors in human vascular endothelial cells. *Biochem. J.* **346**, 835–840 (2000).
69. Batkai, S. & Pachter, P. Endocannabinoids and cardiac contractile function: pathophysiological implications. *Pharmacol. Rev.* **60**, 99–106 (2009).
70. Pachter, P., Batkai, S. & Kunos, G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. *J. Physiol.* **558**, 647–657 (2004).

71. Pacher, P. *et al.* Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. *Am. J. Physiol. Heart Circ. Physiol.* **289**, H533–H541 (2005).
72. Lake, K. D., Compton, D. R., Varga, K., Martin, B. R. & Kunos, G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. *J. Pharmacol. Exp. Ther.* **281**, 1030–1037 (1997).
73. Wagner, J. A. *et al.* Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. *Nature* **390**, 518–521 (1997).
74. Varga, K., Wagner, J. A., Bridgen, D. T. & Kunos, G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. *FASEB J.* **12**, 1035–1044 (1998).
75. Wagner, J. A., Varga, K. & Kunos, G. Cardiovascular actions of cannabinoids and their generation during shock. *J. Mol. Med. (Berl.)* **76**, 824–836 (1998).
76. Batkai, S. *et al.* Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction *in vivo* in cirrhotic rats. *Am. J. Physiol. Heart Circ. Physiol.* **293**, H1689–H1695 (2007).
77. Slavic, S. *et al.* Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. *J. Mol. Med. (Berl.)* **91**, 811–823 (2013).
78. Mukhopadhyay, P. *et al.* Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. *Free Radic. Biol. Med.* **50**, 179–195 (2011).
79. Yang, Y. Y., Liu, H., Nam, S. W., Kunos, G. & Lee, S. S. Mechanisms of TNF α -induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNF α and endocannabinoids. *J. Hepatol.* **53**, 298–306 (2010).
80. Schaich, C. L., Shaltout, H. A., Brosnihan, K. B., Howlett, A. C. & Diz, D. I. Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive [mRen2]27 rats. *Physiol. Rep.* **2**, e12108 (2014).
81. Di Filippo, C., Rossi, F., Rossi, S. & D'Amico, M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. *J. Leukoc. Biol.* **75**, 453–459 (2004).
82. Li, Q., Wang, F., Zhang, Y. M., Zhou, J. J. & Zhang, Y. Activation of cannabinoid type 2 receptor by JWH133 protects heart against ischemia/reperfusion-induced apoptosis. *Cell. Physiol. Biochem.* **31**, 693–702 (2013).
83. Wang, P. F. *et al.* Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. *J. Cardiovasc. Pharmacol.* **59**, 301–307 (2012).
84. Zhang, M. *et al.* Cannabinoid CB₂ receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. *J. Cereb. Blood Flow Metab.* **27**, 1387–1396 (2007).
85. Zhang, M. *et al.* CB₂ receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. *Microvasc. Res.* **78**, 86–94 (2009).
86. Hillard, C. J. Role of cannabinoids and endocannabinoids in cerebral ischemia. *Curr. Pharm. Des.* **14**, 2347–2361 (2008).
87. Zhang, M. *et al.* Modulation of the balance between cannabinoid CB₁ and CB₂ receptor activation during cerebral ischemic/reperfusion injury. *Neuroscience* **152**, 753–760 (2008).
88. Steffens, S. *et al.* Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. *Nature* **434**, 782–786 (2005).
89. Zhao, Y. *et al.* WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. *Eur. J. Pharmacol.* **649**, 285–292 (2010).
90. Zhao, Y. *et al.* Activation of cannabinoid CB₂ receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. *J. Cardiovasc. Pharmacol.* **55**, 292–298 (2010).
91. Netherland, C. D., Pickle, T. G., Bales, A. & Thewke, D. P. Cannabinoid receptor type 2 (CB₂) deficiency alters atherosclerotic lesion formation in hyperlipidemic *Ldlr*-null mice. *Atherosclerosis* **213**, 102–108 (2010).
92. Hoyer, F. F. *et al.* Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells *in vivo*. *J. Mol. Cell. Cardiol.* **51**, 1007–1014 (2011).
93. Willecke, F. *et al.* Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. *PLoS ONE* **6**, e19405 (2011).
94. Freeman-Anderson, N. E. *et al.* Cannabinoid (CB₂) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. *J. Lipid Res.* **49**, 2338–2346 (2008).
95. Pacher, P. Cannabinoid CB₁ receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? *Arterioscler. Thromb. Vasc. Biol.* **29**, 7–9 (2009).
96. Dol-Gleizes, F. *et al.* Rimonabant, a selective cannabinoid CB₁ receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. *Arterioscler. Thromb. Vasc. Biol.* **29**, 12–18 (2009).
97. Sugamura, K. *et al.* Activated endocannabinoid system in coronary artery disease and anti-inflammatory effects of cannabinoid 1 receptor blockade on macrophages. *Circulation* **119**, 28–36 (2009).
98. Jiang, L. S., Pu, J., Han, Z. H., Hu, L. H. & He, B. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. *Cardiovasc. Res.* **81**, 805–813 (2009).
99. Yvan-Charvet, L. *et al.* ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. *Science* **328**, 1689–1693 (2010).
100. Tall, A. R., Yvan-Charvet, L., Westerterp, M. & Murphy, A. J. Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* **32**, 2547–2552 (2012).
101. Tiyerili, V. *et al.* CB₁ receptor inhibition leads to decreased vascular AT₁ receptor expression, inhibition of oxidative stress and improved endothelial function. *Basic Res. Cardiol.* **105**, 465–477 (2010).
102. Lenglet, S. *et al.* Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice. *Arterioscler. Thromb. Vasc. Biol.* **33**, 215–223 (2013).
103. Hoyer, F. F. *et al.* Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. *J. Mol. Cell. Cardiol.* **66**, 126–132 (2014).
104. Montecucco, F. *et al.* Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. *Atherosclerosis* **205**, 433–441 (2009).
105. Jehle, J. *et al.* Myeloid-specific deletion of diacylglycerol lipase α inhibits atherogenesis in ApoE-deficient mice. *PLoS ONE* **11**, e0146267 (2016).
106. Blüher, M. *et al.* Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. *Diabetes* **55**, 3053–3060 (2006).
107. Silvestri, C. & Di Marzo, V. The endocannabinoid system in energy homeostasis and the etiology of metabolic disorders. *Cell Metab.* **17**, 475–490 (2013).
108. Cote, M. *et al.* Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. *Int. J. Obes. (Lond.)* **31**, 692–699 (2007).
109. Wilson, P. W., D'Agostino, R. B., Sullivan, L., Parise, H. & Kannel, W. B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch. Intern. Med.* **162**, 1867–1872 (2002).
110. Di Marzo, V. & Matias, I. Endocannabinoid control of food intake and energy balance. *Nat. Neurosci.* **8**, 585–589 (2005).
111. Despres, J. P., Golay, A. & Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. *N. Engl. J. Med.* **353**, 2121–2134 (2005).
112. Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J. & Rosenstock, J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. *JAMA* **295**, 761–775 (2006).
113. Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D. & Van Gaal, L. F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. *Lancet* **368**, 1660–1672 (2006).
114. Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O. & Rossner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. *Lancet* **365**, 1389–1397 (2005).
115. Van Gaal, L., Pi-Sunyer, X., Despres, J. P., McCarthy, C. & Scheen, A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. *Diabetes Care* **31** (Suppl. 2), S229–S240 (2008).
116. Van Gaal, L. F. *et al.* Long-term effect of CB₁ blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. *Eur. Heart J.* **29**, 1761–1771 (2008).
117. Nissen, S. E. *et al.* Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. *JAMA* **299**, 1547–1560 (2008).
118. Topol, E. J. *et al.* Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet* **376**, 517–523 (2010).
119. O'Leary, D. H. *et al.* Effect of rimonabant on carotid intima-media thickness (CINT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. *Heart* **97**, 1143–1150 (2011).
120. Rumsfeld, J. S. & Nallamothu, B. K. The hope and fear of rimonabant. *JAMA* **299**, 1601–1602 (2008).
121. Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H. & Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet* **370**, 1706–1713 (2007).
122. Quercioli, A. *et al.* Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. *Eur. Heart J.* **32**, 1369–1378 (2011).
123. Quercioli, A. *et al.* Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. *JACC Cardiovasc. Imaging* **5**, 805–815 (2012).
124. Valenta-Schindler, I., Varga, Z. V., Pacher, P. & Schindler, T. Molecular imaging of myocardial cannabinoid type 1 receptor up-regulation in obesity [abstract 197]. *J. Am. Coll. Cardiol.* **69** (Suppl.), 1516 (2017).
125. Cappellano, G. *et al.* Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease. *Can. J. Cardiol.* **29**, 499–509 (2012).
126. Baye, T. M. *et al.* Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. *Pharmacogenomics* **9**, 1647–1656 (2008).
127. Zhang, Y. *et al.* Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent. *Pharmacogenomics* **10**, 1929–1939 (2009).
128. Feng, Q. *et al.* A common CNR1 (cannabinoid receptor 1) haplotype attenuates the decrease in HDL cholesterol that typically accompanies weight gain. *PLoS ONE* **5**, e15779 (2010).
129. Feng, Q. *et al.* A common functional promoter variant links CNR1 gene expression to HDL cholesterol level. *Nat. Commun.* **4**, 1973 (2013).
130. Silver, H. J. *et al.* CNR1 genotype influences HDL-cholesterol response to change in dietary fat intake. *PLoS ONE* **7**, e36166 (2012).
131. Sipe, J. C., Waalen, J., Gerber, A. & Beutler, E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). *Int. J. Obes. (Lond.)* **29**, 755–759 (2005).
132. de Luis, D. A. *et al.* C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance in patients with diabetes mellitus type 2. *Diabetes Res. Clin. Pract.* **88**, 76–80 (2010).
133. Reinhard, W. *et al.* Common polymorphisms in the cannabinoid CB₂ receptor gene (CNR2) are not associated with myocardial infarction and cardiovascular risk factors. *Int. J. Mol. Med.* **22**, 165–174 (2008).
134. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol. Sci.* **30**, 515–527 (2009).
135. Radwan, M. M. *et al.* Isolation and pharmacological evaluation of minor cannabinoids from high-potency *Cannabis sativa*. *J. Nat. Prod.* **78**, 1271–1276 (2015).
136. Mechoulam, R. & Hanus, L. A historical overview of chemical research on cannabinoids. *Chem. Phys. Lipids* **108**, 1–13 (2000).

137. Hampson, A. J., Grimaldi, M., Axelrod, J. & Wink, D. Cannabidiol and Δ^9 -tetrahydrocannabinol are neuroprotective antioxidants. *Proc. Natl Acad. Sci. USA* **95**, 8268–8273 (1998).
138. Weiss, L. *et al.* Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. *Autoimmunity* **39**, 143–151 (2006).
139. Weiss, L. *et al.* Cannabidiol arrests onset of autoimmune diabetes in NOD mice. *Neuropharmacology* **54**, 244–249 (2008).
140. Lehmann, C. *et al.* Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. *Clin. Hemorheol. Microcirc.* **64**, 655–662 (2016).
141. Horvath, B., Mukhopadhyay, P., Hasko, G. & Pacher, P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. *Am. J. Pathol.* **180**, 432–442 (2012).
142. Gruen, G., Barut, F., Kunos, G. & Pacher, P. Role of the endocannabinoid system in diabetes and diabetic complications. *Br. J. Pharmacol.* **173**, 1116–1127 (2016).
143. Durst, R. *et al.* Cannabidiol, a nonpsychoactive cannabis constituent, protects against myocardial ischemic reperfusion injury. *Am. J. Physiol. Heart Circ. Physiol.* **293**, H3602–H3607 (2007).
144. Feng, Y. *et al.* Pharmacologic effects of cannabidiol on acute reperfusion myocardial infarction in rabbits: evaluated with 3.0T cardiac magnetic resonance imaging and histopathology. *J. Cardiovasc. Pharmacol.* **66**, 354–363 (2015).
145. Stanley, C. P., Hind, W. H. & O'Sullivan, S. E. Is the cardiovascular system a therapeutic target for cannabidiol? *Br. J. Clin. Pharmacol.* **75**, 313–322 (2013).
146. Hayakawa, K. *et al.* Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. *Neuroreport* **15**, 2381–2385 (2004).
147. Mishima, K. *et al.* Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine_{1A} receptor-dependent mechanism. *Stroke* **36**, 1077–1082 (2005).
148. Ceprian, M. *et al.* Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. *Neuropharmacology* **116**, 151–159 (2017).
149. Hayakawa, K. *et al.* Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. *J. Neurochem.* **102**, 1488–1496 (2007).
150. Hayakawa, K. *et al.* Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box 1-inhibiting mechanism. *Neuropharmacology* **55**, 1280–1286 (2008).
151. Hayakawa, K. *et al.* Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box 1-inhibiting mechanism. *Biol. Pharm. Bull.* **32**, 1538–1544 (2009).
152. Hao, E. *et al.* Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. *Mol. Med.* **21**, 38–45 (2015).
153. Fouad, A. A., Albulai, W. H., Al-Mulhim, A. S. & Jresat, I. Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. *Environ. Toxicol. Pharmacol.* **36**, 347–357 (2013).
154. Rajesh, M. *et al.* Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. *J. Am. Coll. Cardiol.* **56**, 2115–2125 (2010).
155. Lee, W. S. *et al.* Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. *Mol. Med.* <http://dx.doi.org/10.2119/molmed.2016.00007> (2016).
156. Cunha, J. M. *et al.* Chronic administration of cannabidiol to healthy volunteers and epileptic patients. *Pharmacology* **21**, 175–185 (1980).
157. Devinsky, O. *et al.* Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. *Lancet Neurol.* **15**, 270–278 (2016).
158. Devinsky, O. *et al.* Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. *N. Engl. J. Med.* **376**, 2011–2020 (2017).
159. O'Connell, B. K., Gloss, D. & Devinsky, O. Cannabinoids in treatment-resistant epilepsy: a review. *Epilepsy Behav.* **70**, 341–348 (2017).
160. Yeshurun, M. *et al.* Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. *Biol. Blood Marrow Transplant.* **21**, 1770–1775 (2015).
161. Silvestri, C. *et al.* Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. *J. Hepatol.* **62**, 1382–1390 (2015).
162. Wargent, E. T. *et al.* The cannabinoid Δ^9 -tetrahydrocannabinol (THC) ameliorates insulin sensitivity in two mouse models of obesity. *Nutr. Diabetes* **3**, e68 (2013).
163. Jadon, K. A. *et al.* Efficacy and safety of cannabidiol and tetrahydrocannabinol on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. *Diabetes Care* **39**, 1777–1786 (2016).
164. Englund, A. *et al.* The effect of five day dosing with THC on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. *J. Psychopharmacol.* **30**, 140–151 (2016).
165. Russo, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br. J. Pharmacol.* **163**, 1344–1364 (2011).
166. Waldman, M. *et al.* An ultra-low dose of tetrahydrocannabinol provides cardioprotection. *Biochem. Pharmacol.* **85**, 1626–1633 (2013).
167. Dudok, B. *et al.* Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. *Nat. Neurosci.* **18**, 75–86 (2015).
168. Bilkei-Gorzo, A. *et al.* A chronic low dose of Δ^9 -tetrahydrocannabinol (THC) restores cognitive function in old mice. *Nat. Med.* **23**, 782–787 (2017).
169. Kaskie, B., Ayyagari, P., Milavetz, G., Shane, D. & Arora, K. The increasing use of cannabis among older Americans: a public health crisis or viable policy alternative? *Gerontologist* <http://dx.doi.org/10.1093/geront/gnw166> (2017).
170. Alshaarawy, O. & Anthony, J. C. Cannabis smoking and serum C-reactive protein: a quantile regressions approach based on NHANES 2005–2010. *Drug Alcohol Depend.* **147**, 203–207 (2015).
171. Rajavashisth, T. B. *et al.* Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. *BMJ Open* **2**, e000494 (2012).
172. Muniyappa, R. *et al.* Metabolic effects of chronic cannabis smoking. *Diabetes Care* **36**, 2415–2422 (2013).
173. Hollister, L. E. & Reaven, G. M. Delta-9-tetrahydrocannabinol and glucose tolerance. *Clin. Pharmacol. Ther.* **16**, 297–302 (1974).
174. Jourdan, T. *et al.* Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. *Nat. Med.* **19**, 1132–1140 (2013).
175. Despres, J. P., Ross, R., Boka, G., Almeras, N. & Lemieux, I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. *Arterioscler. Thromb. Vasc. Biol.* **29**, 416–423 (2009).
176. Bedi, G., Cooper, Z. D. & Haney, M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. *Addict. Biol.* **18**, 872–881 (2013).
177. Gorelick, D. A. *et al.* Tolerance to effects of high-dose oral Δ^9 -tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. *J. Anal. Toxicol.* **37**, 11–16 (2013).
178. Huestis, M. A. *et al.* Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. *Arch. Gen. Psychiatry* **58**, 322–328 (2001).
179. Gorelick, D. A. *et al.* The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. *Am. Heart J.* **151**, 754.e1–754.e5 (2006).
180. Huestis, M. A. *et al.* Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. *Psychopharmacology (Berl.)* **194**, 505–515 (2007).
181. Klumpp, L. E. *et al.* Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ^9 -tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. *Br. J. Clin. Pharmacol.* **76**, 65–77 (2013).
182. Agarwal, N. *et al.* Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat. Neurosci.* **10**, 870–879 (2007).
183. Groblewski, T. *et al.* Pre-clinical pharmacological properties of novel peripherally-acting CB1-CB2 agonists. Proceedings of 20th Annual Symposium of the International Cannabinoid Research Society (2010).
184. Groblewski, T. *et al.* Peripherally-acting CB1-CB2 agonists for pain: do they still hold promise? Proceedings of the 20th Annual Symposium of the International Cannabinoid Research Society (2010).
185. Jouanous, E. *et al.* Cannabis use: signal of increasing risk of serious cardiovascular disorders. *J. Am. Heart Assoc.* **3**, e000638 (2014).
186. Casier, I., Vanduyndhoven, P., Haine, S., Vrints, C. & Jorens, P. G. Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. *Acta Cardiol.* **69**, 131–136 (2014).
187. Draz, E. I., Oreby, M. M., Elsheikh, E. A., Khedr, L. A. & Atlam, S. A. Marijuana use in acute coronary syndromes. *Am. J. Drug Alcohol Abuse* **43**, 576–582 (2016).
188. Flesch, M. & Erdmann, E. Racing heart and angina pectoris in a 19-year-old male. Possibly the result of cannabis smoking? [German]. *MMW Fortschr. Med.* **146**, 16 (2004).
189. Marchetti, D., Spagnolo, A., De Matteis, V., Filograna, L. & De Giovanni, N. Coronary thrombosis and marijuana smoking: a case report and narrative review of the literature. *Drug Test. Anal.* **8**, 56–62 (2016).
190. Hodcroft, C. J., Rossiter, M. C. & Buch, A. N. Cannabis-associated myocardial infarction in a young man with normal coronary arteries. *J. Emerg. Med.* **47**, 277–281 (2014).
191. Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B. & Muller, J. E. Triggering myocardial infarction by marijuana. *Circulation* **103**, 2805–2809 (2001).
192. Frost, L., Mostofsky, E., Rosenbloom, J. I., Mukamal, K. J. & Mittleman, M. A. Marijuana use and long-term mortality among survivors of acute myocardial infarction. *Am. Heart J.* **165**, 170–175 (2013).
193. Arora, S., Goyal, H., Aggarwal, P. & Kukar, A. ST-segment elevation myocardial infarction in a 37-year-old man with normal coronaries — it is not always cocaine! *Am. J. Emerg. Med.* **30**, 2091.e3–2091.e5 (2012).
194. Kocabay, G., Yildiz, M., Duran, N. E. & Ozkan, M. Acute inferior myocardial infarction due to cannabis smoking in a young man. *J. Cardiovasc. Med. (Hagerstown)* **10**, 669–670 (2009).
195. Cappelli, F., Lazzari, C., Gensini, G. F. & Valente, S. Cannabis: a trigger for acute myocardial infarction? A case report. *J. Cardiovasc. Med. (Hagerstown)* **9**, 725–728 (2008).
196. Mukamal, K. J., Maclure, M., Muller, J. E. & Mittleman, M. A. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. *Am. Heart J.* **155**, 465–470 (2008).
197. Ting, J. Y. Reversible cardiomyopathy associated with acute inhaled marijuana use in a young adult. *Clin. Toxicol. (Phila.)* **45**, 432–434 (2007).
198. Nogi, M., Fergusson, D. & Chiao, J. M. Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case report. *Hawaii J. Med. Publ. Health* **73**, 115–118 (2014).
199. Singh, A. *et al.* Marijuana (cannabis) use is an independent predictor of stress cardiomyopathy in young men [abstract]. *Circulation* **134**, A14100 (2016).
200. Kalla, A., Krishnamoorthy, P., Gopalakrishnan, A., Gang, J. & Figueredo, V. Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the national inpatient sample [abstract]. *J. Am. Coll. Cardiol.* **69**, 1784 (2017).
201. Lou, J. Y., Randhawa, M. S., Hornacek, D. & Bajzer, C. Images in vascular medicine. Spontaneous renal artery dissection in a cannabis user. *Vasc. Med.* **20**, 379–380 (2015).
202. Charbonney, E., Stajzel, J. M., Poletti, P. A. & Rutschmann, O. Paroxysmal atrial fibrillation after recreational marijuana smoking: another “holiday heart”? *Swiss Med. Wkly* **135**, 412–414 (2005).
203. Korantzopoulos, P. Marijuana smoking is associated with atrial fibrillation. *Am. J. Cardiol.* **113**, 1085–1086 (2014).

204. Singh, D., Huntwork, M., Shetty, V., Sequeira, G. & Akingbola, O. Prolonged atrial fibrillation precipitated by new-onset seizures and marijuana abuse. *Pediatrics* **133**, e443–e446 (2014).
205. Akins, D. & Awdeh, M. R. Marijuana and second-degree AV block. *South. Med. J.* **74**, 371–373 (1981).
206. Pratap, B. & Korniyenko, A. Toxic effects of marijuana on the cardiovascular system. *Cardiovasc. Toxicol.* **12**, 143–148 (2012).
207. Sanchez Lazaro, I. J., Almenar Bonet, L., Sancho-Tello, M. J. & Martinez-Dolz, L. Ventricular tachycardia due to marijuana use in a heart transplant patient. *Rev. Esp. Cardiol.* **62**, 459–461 (2009).
208. Baranchuk, A., Johri, A. M., Simpson, C. S., Methot, M. & Redfearn, D. P. Ventricular fibrillation triggered by marijuana use in a patient with ischemic cardiomyopathy: a case report. *Cases J.* **1**, 373 (2008).
209. Brancheau, D., Blanco, J., Gholkar, G., Patel, B. & Machado, C. Cannabis induced asystole. *J. Electrocardiol.* **49**, 15–17 (2016).
210. Hartung, B., Kauferstein, S., Ritz-Timme, S. & Daldrup, T. Sudden unexpected death under acute influence of cannabis. *Forensic Sci. Int.* **237**, e11–e13 (2014).
211. Reis, J. P. *et al.* Cumulative lifetime marijuana use and incident cardiovascular disease in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Am. J. Public Health* **107**, 601–606 (2017).
212. Falkstedt, D., Wolff, V., Allebeck, P., Hemmingsson, T. & Danielsson, A. K. Cannabis, tobacco, alcohol use, and the risk of early stroke: a population-based cohort study of 45 000 Swedish men. *Stroke* **48**, 265–270 (2017).
213. Di Napoli, M. *et al.* Prior cannabis use is associated with outcome after intracerebral hemorrhage. *Cerebrovasc. Dis.* **41**, 248–255 (2016).
214. Rumalla, K., Reddy, A. Y. & Mittal, M. K. Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States. *J. Neurol. Sci.* **364**, 191–196 (2016).
215. Rumalla, K., Reddy, A. Y. & Mittal, M. K. Association of recreational marijuana use with aneurysmal subarachnoid hemorrhage. *J. Stroke Cerebrovasc. Dis.* **25**, 452–460 (2016).
216. Behrouz, R. *et al.* Cannabis use and outcomes in patients with aneurysmal subarachnoid hemorrhage. *Stroke* **47**, 1371–1373 (2016).
217. Hemachandra, D., McKetin, R., Cherbuin, N. & Anstey, K. J. Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. *Aust. N. Z. J. Public Health* **40**, 226–230 (2016).
218. Jouanous, E., Raymond, V., Lapeyre-Mestre, M. & Wolff, V. What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review. *Curr. Atheroscler. Rep.* **19**, 26 (2017).
219. Wolff, V. & Jouanous, E. Strokes are possible complications of cannabinoids use. *Epilepsy Behav.* **70**, 355–363 (2017).
220. Han, K. H. *et al.* CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. *Cardiovasc. Res.* **84**, 378–386 (2009).
221. Jourdan, T. *et al.* Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. *Proc. Natl Acad. Sci. USA* **111**, E5420–E5428 (2014).
222. Pacher, P., Beckman, J. S. & Liaudet, L. Nitric oxide and peroxynitrite in health and disease. *Physiol. Rev.* **87**, 315–424 (2007).
223. Yankey, B. A. *et al.* Effect of marijuana use on cardiovascular and cerebrovascular mortality: a study using the National Health and Nutrition Examination Survey linked mortality file. *Eur. J. Prev. Cardiol.* <http://dx.doi.org/10.1177/2047487317723212> (2017).
224. Wang, X. *et al.* One minute of marijuana secondhand smoke exposure substantially impairs vascular endothelial function. *J. Am. Heart Assoc.* **5**, e003858 (2016).
225. Mir, A., Obafemi, A., Young, A. & Kane, C. Myocardial infarction associated with use of the synthetic cannabinoid K2. *Pediatrics* **128**, e1622–e1627 (2011).
226. Ibrahim, S., Al-Saffar, F. & Wannenburg, T. A. Unique case of cardiac arrest following K2 abuse. *Case Rep. Cardiol.* **2014**, 120607 (2014).
227. Patton, A. L. *et al.* K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. *J. Forensic Sci.* **58**, 1676–1680 (2013).
228. Davis, C. & Boddington, D. Teenage cardiac arrest following abuse of synthetic cannabis. *Heart Lung Circ.* **24**, e162–e163 (2015).
229. Shah, M., Garg, J., Patel, B., Guthrie, J. & Freudenberger, R. S. Can your heart handle the spice: a case of acute myocardial infarction and left ventricular apical thrombus. *Int. J. Cardiol.* **215**, 129–131 (2016).
230. Labay, L. M. *et al.* Synthetic cannabinoid drug use as a cause or contributory cause of death. *Forensic Sci. Int.* **260**, 31–39 (2016).
231. Orsini, J. *et al.* The wide and unpredictable scope of synthetic cannabinoids toxicity. *Case Rep. Crit. Care* **2015**, 542490 (2015).
232. Atik, S. U. *et al.* Cardiovascular side effects related with use of synthetic cannabinoids “bonzai”: two case reports. *Türk Pediatri Ars.* **50**, 61–64 (2015).
233. Obafemi, A. I., Kleinschmidt, K., Goto, C. & Fout, D. Cluster of acute toxicity from ingestion of synthetic cannabinoid-laced brownies. *J. Med. Toxicol.* **11**, 426–429 (2015).
234. Hermanns-Clausen, M. *et al.* Adverse effects after the use of JWH-210 — a case series from the EU Spice II plus project. *Drug Test. Anal.* **8**, 1030–1038 (2016).
235. Hill, S. L. *et al.* Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. *Clin. Toxicol. (Phila.)* **54**, 638–643 (2016).
236. Monte, A. A. *et al.* Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: a ToxIC Database study. *J. Med. Toxicol.* **13**, 146–152 (2017).
237. Andonian, D. O., Seaman, S. R. & Josephson, E. B. Profound hypotension and bradycardia in the setting of synthetic cannabinoid intoxication — a case series. *Am. J. Emerg. Med.* **35**, 940.e5–940.e6 (2017).
238. Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use — multiple states, 2012. *MMWR Morb. Mortal. Wkly Rep.* **62**, 93–98 (2013).
239. Zarifi, C. & Vyas, S. Spice-y kidney failure: a case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis. *Perm. J.* <http://dx.doi.org/10.7812/TPP/16-160> (2017).
240. Maccarrone, M. *et al.* Endocannabinoid signaling at the periphery: 50 years after THC. *Trends Pharmacol. Sci.* **36**, 277–296 (2015).
241. Mukhopadhyay, P. *et al.* CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. *Br. J. Pharmacol.* **160**, 657–668 (2010).
242. Barutta, F. *et al.* Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. *Diabetes* **59**, 1046–1054 (2010).
243. Jourdan, T. *et al.* Developmental role of macrophage cannabinoid-1 receptor signaling in type 2 diabetes. *Diabetes* **66**, 994–1007 (2017).

Acknowledgements

The authors are supported by the Intramural Program of the NIAAA/NIH.

Author contributions

P.P. and S.S. researched data for the article. All the authors discussed the content of the manuscript. P.P., S.S., and G.K. wrote the article, and P.P., G.H., T.H.S., and G.K. reviewed/edited the manuscript before submission.

Competing interests statement

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.